Detailed below is a fourth achievement the Immune Tolerance Network (ITN) recently presented at the Member Society Symposium at the Federation of Clinical Immunology Societies (FOCiS) meeting, and how this work fits in with the broader pursuit of tolerance in allergy.
Detailed below is a third achievement the Immune Tolerance Network (ITN) recently presented at the Member Society Symposium at the Federation of Clinical Immunology Societies (FOCiS) meeting, and how this work fits in with the broader pursuit of tolerance in transplantation.
Detailed below is a second achievement the Immune Tolerance Network (ITN) recently presented at the Member Society Symposium at the Federation of Clinical Immunology Societies (FOCiS) meeting, and how this work fits in with the broader pursuit of tolerance in autoimmunity.
Achieving clinical tolerance in allergy, autoimmunity and solid organ transplantation is a daunting challenge due to the complex and multi-faceted nature of the immune system. Part of the ITN’s mission is to unravel the mechanisms of tolerance to better target future strategies for inducing tolerance, and to disseminate these findings.
This is a reminder that the Immune Tolerance Network (ITN) is currently seeking short "Concept Proposals" for novel combination therapy clinical trials designed to induce immune tolerance in allergy and asthma. The ITN is especially interested in the following:
1) Studies with a tolerance endpoint that combine allergen-specific approaches with other immunomodulatory agents
The ACCESS ITN034AI clinical trial for lupus nephritis achieved a milestone by completing enrollment of 137 participants, five months ahead of schedule. ACCESS is a randomized, placebo-controlled research study for participants 16 years of age or older who have been diagnosed with lupus and who have developed complications in their kidneys.
Data from an Immune Tolerance Network (ITN) peanut allergy pilot study will be presented in an oral abstract at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) annual meeting in Geneva, Switzerland on June 16-20, 2012:
Functional but not quantitative peanut-specific IgE antibodies as diagnostic marker for peanut allergy. (Mohamed Shamji, PhD, Imperial College London)
The Immune Tolerance Netowork (ITN) is hosting a Member Society Symposium entitled “A View Towards (Immune) Tolerance” on June 20th, 2012 at the Federation of Clinical Immunology Societies (FOCIS) annual meeting in Vancouver, BC, Canada.
The symposium highlights ITN’s recent clinical and mechanistic achievements in allergy, autoimmunity, and solid organ transplantation. The list of talks and speakers is below:
Data from two ITN transplant trials will be reported at the upcoming American Transplant Congress (ATC) meeting in Boston, MA on June 2-6, 2012.
Preliminary results from the A-WISH ITN030ST study, which examines feasibility of immunosuppression withdrawal in hepatitis C or non-immune non-viral liver transplant patients, will be reported in the abstract:
In a recently published review in the American Journal of Transplantation, ITN authors Nadia Tchao, MD and Laurence Turka, MD discuss the biology of lymphocyte depletion and considerations for strategies that aim to promote pro-tolerogenic reconstitution in transplant settings. The depletion of lymphocytes (T cells and B cells) is a strategy increasingly being used to help prevent rejection in transplant settings by reducing the pool of alloreactive cells.